Occupancy of striatal and extrastriatal dopamine D2/D 3 receptors by olanzapine and haloperidol

Neuropsychopharmacology

Volumn 30, Issue 12, 2005, Pages 2283-2289

  Kessler, Robert M ^a   Ansari, Mohammad Sib ^a   Riccardi, Patrizia ^a   Li, Rui ^a,b   Jayathilake, Karuna ^a   Dawant, Benoit ^b   Meltzer, Herbert Y ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

Atypical antipsychotic drug; Dopamine D2 D3 receptor; Haloperidol; Olanzapine; PET; Substantia nigra

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; FLUORINE 18; HALOPERIDOL; OLANZAPINE; SEROTONIN 2A RECEPTOR; SETOPERONE;

ADULT; AMYGDALOID NUCLEUS; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS STRIATUM; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; SCHIZOPHRENIA; SUBSTANTIA NIGRA; TEMPORAL CORTEX; THALAMUS;

ADULT; ANTIPSYCHOTIC AGENTS; BENZAMIDES; BENZODIAZEPINES; BRAIN CHEMISTRY; CORPUS STRIATUM; DOPAMINE ANTAGONISTS; FEMALE; HALOPERIDOL; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PYRIMIDINONES; PYRROLIDINES; RADIOPHARMACEUTICALS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D3; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS;

EID: 27844538830     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300836     Document Type: Article

References (58)

1. Andersson JL, Nomikos GG, Marcus M, Hertel P, Mathe JM, Svensson TH et al (1995). Ritanserin potentiates the stimulatory effects of raclopopride on neuronal activity and dopamine release selectively in the mesolimbic dopaminergic system. Naunyn-Schmiedebergs Arch Pharmacol 352: 374-385.
2. Beasley CM, Tollefson G, Tran P, Saterlee W, Sanger T, Hamilton S et al (1996). Olanzapine vs placebo and haloperidol acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14: 111-123.
3. Bersani G, Grispini A, Marini S, Pasini A, Valducci M, Ciani N (1990). 5-HT2A antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo. Clin Neuropharmacol 13: 500-506.
4. 123I] epidepride single photon emission tomography (SPET) study. Psychopharmacology 150: 132-140.
5. 18F]setopeone by a noninvasive reference region graphical method. In: Carson R, Herscovitch P, Daube-Witnerspoon M (eds). Quantitative Functional Brain Imaging with Positron Emission Tomography. Academic Press: New York. pp 421-426.
6. Bruggeman RM, Heeringa M, Westerink BHC, Timmerman W (2000). Combined 5-HT2A/D2/D3receptor blockade inhibits the firing rate of SNR neurons in the rat brain. Prog Neuro-Psychopharmacol Biol Psychiatr 24: 579-593.
7. Buchsbaum MS, Christian BT, Lehrer DS, Mukherjee J, Shi B, Moutil J (2004). D2/D3/D3 dopamine receptor binding in the thalamus of medication-naïve schizophrenics. Int J Neuropsychopharm 7: S430.
8. Bymaster FP, Calligaro DO, Falcone JR, Marsh RD, Moore NA, Tye NC et al (1996). Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14: 87-96.
9. Chiodo LA, Bunney BS (1983). Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 3: 1607-1619.
10. Crocker AD, Hemsley KM (2001). An animal model of extrapyramidal side effects induced by antipsychotic drugs: relationship with D2/D3 dopamine receptor occupancy. Prog Neuro-Psychoparhamcol Biol Psychiat 25: 573-590.
11. Double KL, Crocker AS (1995). Dopamine receptors in the substantia nigra are involved in the regulation of muscle tone. Proc Natl Acad Sci USA 92: 1669-1673.
12. 123I] epidepride: resolving conflicting findings. Neuroimage 19: 1205-1214.
13. 123I] epidepride binding to striatal and extrastriatal dopamine D2/D3 receptors. Synapse 34: 290-304.
14. Gerhardt GA, Cass WA, Huettl P, Brock S, Zhang ZM, Gash DM (1999). GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys. Brain Res Rev 817: 163-171.
15. Gerhardt GA, Cass WA, Yi A, Zhang Z, Gash DM (2002). Changes in somatodendritic but not terminal dopamine regulation in aged rhesus monkeys. J Neurochem 80: 168-177.
16. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ (1997). Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 6: 279-287.
17. Hemsley KM, Crocker AD (1999). Raclopride and chlorpromazine, but not clozapine, increase muscle rigidity in the rat: relationship with D2/D3 dopamine receptor occupancy. Neuropsychopharmacology 21: 101-109.
18. Janowsky A, Neve KA, Kinzie JM, Taylor B, dePaulis T, Belknap JK (1992). Extrastriatal dopamine D2/D3 receptors: distribution pharmacological characterization and region-specific regulation by clozapine. J Pharmacol Exp Ther 261: 1282-1290.
19. Kapur S, Jones C, DaSilva J, Wilson A, Houle S (1997). Reliability of a simple non-invasive method for the evaluation of 5-HT2A receptors using [18F]-setoperone PET imaging. Nucl Med Com 18: 395-399.
20. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA et al (1998). 5-HT2A and D2/D3 receptor occupancy of olanzapine in schizophrenia: a PET investigation. AM J Psychiatry 155: 921-928.
21. Kapur S, Zipursky RB, Remington G (1999). Clinical and theoretical implications of 5-HT2A and D2/D3 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156: 286-293.
22. Kessler R, Ansari AS, Li R, Lee M, Schmidt D, Dawant B et al (2002). Occupancy of cortical and substantia nigra DA D2/D3 receptors by typical and atypical antipsychotic drugs. Neuroimage 16: 59.
23. Kessler RM, Ellis JR, Eden M (1984). Analysis of emission tomographic scan data: limitations imposed by resolution and background. J Comput Assist Tomogr 8: 514-522.
24. 18F] N-ally-5-fluorproplepidepride (fallypride): radiation dosimetry, quantification of striatal and extrastriatal dopamine receptors in man. Neuroimage 11: S32.
25. 11C] racolpride studies. J Cerebral Blood Flow Metab 16: 42-52.
26. 2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res 947: 157-165.
27. A/C agonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release. Psychopharmacology 131: 57-63.
28. Maes F, Collignon A, Vandermuele D, Marchai G, Suetens P (1997). Multimodality image registration by maximization of mutual information. IEEE Trans Med Imag 16: 187-198.
29. Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR et al (2001). Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptors parameter measurements in ventral striatum. J Cereb Blood Flow Metab 21: 1034-1057.
30. Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003). Serotonin receptors: their key role in drugs to treat schizophrenia. Progr Neuropsychopharmacol Biol Psychiatr 27: 1159-1172.
31. i values. J Pharmacol Exp Therap 251: 238-251.
32. Meltzer HY, McGurk SR (1999). The effect of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophrenia Bull 25: 233-255.
33. 18F-fallypride in normal volunteers: blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. Synapse 46: 170-188.
34. Nordstrom AL, Nyberg S, Olsson H, Farde L (1998). Positron emission tomography finding of a high striatal D2/D3 receptor occupancy in olanzapine-treated patients. Arch Gen Psychiatry 55: 283-284.
35. Olsson H, Farde L (2001). Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2/D3 receptor occupancy - a simulation study based on experimental data. NeuroImage 14: 936-945.
36. Petit-Taboue MC, Landeau B, Osmont A, Tillet I, Barre L, Baron JC (1996). Estimation of neocortical serotonin-2 receptor binding potential by single-dose fluorine-18-Setoperone kinetic PET data analysis. J Nucl Med 37: 95-104.
37. 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology 124: 148-153.
38. Raedler TJ, Knable MB, Lafargue T, Urbina RA, Egan MF, Pickar D et al (1999). In vivo determination of striatal dopamine D2/D3 receptor occupancy in patients treated with olanzapine. Psychiatr Res: Neuroimaging Section 90: 81-90.
39. Robertson GS, Robertson HA (1989). Evidence that L-Dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms. J Neurosci 9: 3326-3331.
40. Robertson GS, Fibiger HC (1992). Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46: 315-328.
41. Robertson GS, Matsumura H, Fibiger HC (1994). Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J PET 271: 1058-1066.
42. Robertson GS, Fibiger HC (1996). Effects of olanzapine on regional C-FOS expression in rat forebrain. Neuropsychopharmacology 14: 105-110.
43. Roth BL, Tandra S, Burgess LH, Sibley DR, Meltzer HY (1995). D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology 120: 365-368.
44. Schotte A, Janssen PFM, Gommeren W, Luyten WH, VanGompel P, Lesage AS et al (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124: 57-73.
45. Sorenson SM, Kehne JH, Fadayel GM, Humphreys TM, Ketteler HJ, Sullivan CK et al (1993). Characterization of the 5-HT2A receptor antagonist MLD 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther 266: 684-691.
46. Stockton ME, Rasmussen K (1996). Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropharmacology 14: 97-105.
47. Talairach J, Tournoux P (1988). Co-Planar Stereotaxic Atlas of the Human Brain. Thieme: New York.
48. 11C]FLB457. Int J Neuropsychopharmacol 6: 361-370.
49. Tarazi FI, Zhang K, Baldessarini RJ (2001). Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J Pharmacol Exp Therap 297: 711-717.
50. 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy I schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacology 141: 175-181.
51. Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S (2002). Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatr Res 7: 317-321.
52. Timmerman W, Heijmen M, Westerink BH, Bruggeman R, denBoer JA (1999). Effects of acute and chronic administration of olanzapine in comparison to clozapine and haloperidol on extracellular recordings of substantia nigra reticulata neurons in the rat brain. Psychopharmacologia 144: 286-294.
53. Trichard C, Paillere-Martinot ML, Attar-Levy D, Recassens C, Monnet F, Martinot JL (1998). Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am J Psychiatry 155: 505-508.
54. Tuppurainen H, Kuikka J, Viinamaki H, Husso-Saastamoinen M, Bergstrom K, Tiihonen J (2003). Extrastriatal dopamine D2/D3/3 receptor density and distribution in drug-naïve schizophrenic patients. Mol Psychiatry 8: 453-455.
55. Vernaleken I, Siessmeier T, Buchholz HG, Hartter S, Hiemke C, Stoeter P et al (2004). High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. Int J Neuropsychopharmacol 7: 421-430.
56. Wells WM, Viola P, Atsumi H, Nakajima S, Kikinis R (1996). Multimodal volume registration by maximization of mutual information. Med Imag Anal 1: 35-51.
57. Xiberas X, Marinot JL, Mallet L, Artiges E, Loc'h C, Maziere B et al (2000). Extrastriatal and striatal D2/D3 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatr 179: 503-508.
58. Yasuno F, Suhara T, Okubo Y, Sudo Y, Inoue M, Ichimiya T et al (2004). Low dopamine d(2) receptor binding in subregions of the thalamus in schizophrenia. Am J Psychiatry 161: 1016-1022.